Bysanti FDA Approval: Treatment for Schizophrenia & Bipolar I

The formal approval of Bysanti (milsaperidone) by the United States Food and Drug Administration (FDA) on February 20, 2026, signifies a sophisticated regulatory and pharmacological evolution within the atypical antipsychotic class. Indicated for the treatment of schizophrenia and the acute management of manic or mixed episodes associated with bipolar I disorder in adults, Bysanti enters the therapeutic landscape as a new chemical entity (NCE) developed by Vanda Pharmaceuticals. The approval of this medication is grounded in a unique regulatory strategy that successfully leveraged the established clinical heritage and extensive safety database of iloperidone (Fanapt), a second-generation antipsychotic previously approved for similar indications. This report provides an exhaustive examination of the pharmacological profile, clinical efficacy, and safety considerations of Bysanti, framing its utility within the broader context of contemporary neuropsychiatric care.   

Regulatory Status and Indications

The FDA’s decision to grant marketing authorization for Bysanti on February 20, 2026, follows a rigorous review of a New Drug Application (NDA) that utilized bioequivalence data to link the novel compound milsaperidone with its active metabolic counterpart, iloperidone. This regulatory pathway permitted the incorporation of long-standing safety and efficacy evidence from iloperidone’s development program—which comprises over 100,000 patient-years of real-world and clinical trial experience—into the review framework for Bysanti.   

FDA-Approved Indications

Bysanti is indicated for the following therapeutic uses in adult populations:

• Treatment of schizophrenia in adults.   
• Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.   

The labeling characterizes Bysanti as a frontline therapeutic option, designed to address the complex neurobiological underpinnings of psychosis and mood dysregulation. As a new chemical entity, Bysanti is expected to be protected by regulatory data exclusivity and issued U.S. patents through at least 2044, providing a substantial intellectual property runway that supports continued investment in the molecule’s lifecycle.   

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for the treatment of patients with dementia-related psychosis.   

Risk Evaluation and Mitigation Strategy (REMS)

As of the initial approval documentation, Bysanti is not subject to a specific Risk Evaluation and Mitigation Strategy (REMS) beyond the standard requirements for atypical antipsychotics. However, clinicians must adhere strictly to the monitoring guidelines specified in the “Warnings and Precautions” section of the prescribing information, particularly concerning cardiac and metabolic parameters.   

Pharmacological Characterization and Mechanism of Action

The clinical utility of Bysanti is rooted in the pharmacological properties of its active ingredient, milsaperidone. Milsaperidone is an active metabolite of iloperidone, and upon oral administration, the two compounds undergo rapid interconversion. This metabolic relationship creates a therapeutic environment characterized by “dual active molecules” that work in tandem to modulate critical neurotransmitter pathways in the central nervous system.   

Neuroreceptor Binding Profile

Bysanti functions as an atypical antipsychotic with a multi-receptor binding fingerprint. Its efficacy in managing schizophrenia and bipolar I disorder is attributed to a combination of dopamine and serotonin receptor antagonism.   

A distinguishing feature of Bysanti’s pharmacological profile is its potent α1​-adrenergic receptor antagonism, which is quantitatively greater than its binding affinity for dopamine or serotonin receptors. This unique weighting of receptor interactions is hypothesized to provide specific benefits in controlling symptoms of hostility, agitation, and hyperarousal—features often associated with acute psychotic and manic states. The potent α1​-antagonism also underlies the medication’s propensity for causing orthostatic hypotension, necessitating the rigorous titration schedule required at treatment initiation.   

Bioequivalence and Systemic Exposure

The pharmacological identity between Bysanti and the established agent iloperidone was a central pillar of its regulatory approval. Clinical studies demonstrated that milsaperidone is bioequivalent to iloperidone across the entire therapeutic dosing range.   

Note: GMR indicates the Geometric Mean Ratio for Cmax​ and AUC between milsaperidone and iloperidone.   

This bioequivalence ensures that clinicians can translate the extensive clinical findings and dosage guidelines from the iloperidone database directly to the use of Bysanti. Once absorbed, the interconversion between the parent drug and its metabolite leads to consistent systemic exposure to the active moieties regardless of the initial compound administered.   

Clinical Efficacy in Schizophrenia

The evidence supporting the use of Bysanti in schizophrenia is derived from multiple randomized, double-blind, placebo-controlled and active-controlled trials. These studies focused on both acute symptom reduction and long-term maintenance of stability.   

Acute Exacerbation Trials

The primary efficacy program for schizophrenia included short-term (4-to-6 week) trials in adults meeting DSM criteria for schizophrenia.   

• Study 1 (N=706): This trial evaluated flexible dose ranges of the active moiety (12-16 mg/day or 20-24 mg/day) against placebo and an active control (risperidone). The primary endpoint was the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at the end of treatment. Both active dose groups demonstrated statistically significant superiority to placebo (p < 0.05).   
• Study 2 (N=604): A 4-week trial comparing 24 mg daily doses to placebo and ziprasidone. The results further corroborated the efficacy of the treatment, showing significant reductions in PANSS total scores relative to placebo.   

Maintenance and Relapse Prevention

The REPRIEVE study (NCT01291511) provided critical data regarding the long-term effectiveness of the active moiety in preventing relapse in patients with schizophrenia. This randomized withdrawal study followed 303 clinically stable adult outpatients who had completed a 12-week open-label stabilization period on doses of 8-24 mg/day.   

The findings from REPRIEVE indicate that continued therapy provides a substantial protective effect against symptom recurrence, nearly doubling the time to relapse compared to discontinuation of therapy.   

Clinical Efficacy in Bipolar I Disorder

The approval of Bysanti for the acute treatment of manic or mixed episodes in bipolar I disorder was supported by a Phase III study (NCT04819776) completed in 2024.   

Pivotal Bipolar Mania Trial (NCT04819776)

In this randomized, double-blind, placebo-controlled study, 414 adults hospitalized with acute manic or mixed features were randomized 1:1 to receive either the active moiety (up to 24 mg/day) or placebo for 4 weeks.   

The primary efficacy measure was the change from baseline to Week 4 in the Young Mania Rating Scale (YMRS) total score.   

Note: Data derived from the pivotal Phase III bipolar mania study.   

The study achieved its primary and key secondary endpoints, demonstrating that the treatment produced significantly greater improvements in manic symptoms than placebo as early as Day 14. Secondary outcome measures, including the Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impression of Change (CGI-C) scales, also showed statistically significant improvements. Furthermore, post hoc analyses highlighted that treatment significantly improved the YMRS sleep item, addressing both the reduced sleep duration and the decreased perceived need for sleep that are hallmarks of acute mania.   

Safety and Tolerability Profile

The safety profile of Bysanti is closely aligned with the established profile of iloperidone, reflecting its bioequivalent systemic exposure. Clinicians should evaluate the potential for adverse reactions across several physiological systems.   

Common Adverse Reactions

Adverse reactions observed with an incidence of ≥5% and at least twice the rate of placebo in clinical trials are listed below.   

In the schizophrenia studies, patients experienced an average weight gain of approximately 6 lbs over 4–6 weeks, while in the bipolar studies, the average weight gain was 7 lbs over 4 weeks.   

Cardiac Risks and QTc Prolongation

Bysanti is associated with a dose-related prolongation of the QTc interval. Clinical studies observed a maximal prolongation of 42.7±10.2 ms after a significant dose. This prolongation can increase the risk of Torsade de Pointes and sudden death.   

Specific precautions include:

• Avoidance of Bysanti in combination with other drugs known to prolong the QTc interval (e.g., Class IA or Class III antiarrhythmics, certain antipsychotics).   
• Monitoring of serum potassium and magnesium at baseline and periodically in patients at risk for electrolyte disturbances.   
• Dose reduction or discontinuation if the QTc interval persistently exceeds 500 msec.   

Orthostatic Hypotension and Syncope

Due to its potent α1​-adrenergic antagonism, Bysanti carries a significant risk of orthostatic hypotension and syncope. This risk is most acute during the initial titration phase. Monitoring of orthostatic vital signs is recommended for patients who are vulnerable to hypotension, including the elderly and those with cardiovascular or cerebrovascular disease.   

Metabolic and Other class-wide Warnings

Long-term use of atypical antipsychotics like Bysanti is associated with metabolic changes.   

• Hyperglycemia: Extreme cases of hyperglycemia, sometimes leading to ketoacidosis or hyperosmolar coma, have been reported.   
• Dyslipidemia: Significant changes in fasting lipids have been observed.   
• Neuroleptic Malignant Syndrome (NMS): This rare, potentially fatal syndrome requires immediate discontinuation and intensive monitoring.   
• Tardive Dyskinesia (TD): The risk of developing TD and the likelihood of it becoming irreversible increase with the duration of treatment and cumulative dose.   
• Blood Dyscrasias: Cases of leukopenia, neutropenia, and agranulocytosis have been reported. Bysanti should be discontinued if the absolute neutrophil count (ANC) falls below 1,000/mm3.   
• Hyperprolactinemia: Like other D2​ antagonists, Bysanti elevates prolactin levels, which may cause galactorrhea, gynecomastia, or amenorrhea.   

Dosage and Administration

Bysanti is administered orally twice daily without regard to food. To minimize the risk of orthostatic hypotension, the medication must be titrated according to specific schedules for each indication.   

Titration Schedule for Adults

Note: For schizophrenia, patients may either follow the full 7-day titration to 12 mg BID or, starting on Day 5, continue at 6 mg BID based on individual tolerability and response. The recommended maintenance range for schizophrenia is 6–12 mg BID, while the maintenance dose for bipolar mania is 12 mg BID.   

Adjustments in Special Populations

• CYP2D6 Poor Metabolizers: These individuals exhibit higher drug exposure and require a 50% reduction in the total daily dose. A specialized titration pack (Titration Pack C) is available for these patients.   
• Strong CYP2D6/CYP3A4 Inhibitors: Concurrent use with potent inhibitors (e.g., paroxetine, fluoxetine, ketoconazole) necessitates a 50% dose reduction of Bysanti.   
• Hepatic Impairment: No dose adjustment is required for mild impairment (Child-Pugh class A). Caution and lower maintenance doses are advised for moderate impairment (Child-Pugh class B). Bysanti is not recommended for patients with severe hepatic impairment (Child-Pugh class C).   
• Lactation: It is advised not to breastfeed during treatment and for a specified period after the last dose (6 days for normal metabolizers; 8 days for poor metabolizers).   

Competitive Landscape and Future Directions

The introduction of Bysanti provides an additional evidence-based tool in a competitive atypical antipsychotic market that includes established molecules such as Vraylar (cariprazine) and newer entries like Cobenfy (xanomeline/trospium).   

Comparison with Contemporary Antipsychotics

While Bysanti shares a mechanism of action with many second-generation antipsychotics, its unique α1​-adrenergic receptor binding profile distinguishes it as a potential option for patients where agitation is a primary clinical concern. Unlike newer muscarinic-based therapies, Bysanti leverages a well-characterized safety profile with over a decade of clinical heritage.   

Pipeline Expansion and Lifecycle Management

Vanda Pharmaceuticals is actively pursuing the expansion of Bysanti’s clinical utility beyond its current indications.   

• Major Depressive Disorder (MDD): Bysanti is currently being evaluated in Phase III trials as a once-daily adjunctive treatment for treatment-resistant MDD. Results from these trials are expected by the end of 2026.   
• Long-Acting Injectable (LAI) Development: The physicochemical properties of milsaperidone, including its potential for lipid ester formulation, make it an attractive candidate for future long-acting injectable development, which could improve adherence in chronic schizophrenia.   

Conclusion

Bysanti (milsaperidone) represents a significant regulatory and clinical milestone, offering a novel chemical entity that provides continuity with a trusted pharmacological mechanism. Its dual active molecule profile, combined with potent α1​-adrenergic antagonism, provides a nuanced therapeutic option for the management of schizophrenia and acute bipolar I disorder. As Bysanti becomes commercially available in late 2026, its long-term exclusivity and ongoing clinical investigations in depression and long-acting formulations position it as a foundational component of Vanda Pharmaceuticals’ psychiatric portfolio. Clinicians utilizing Bysanti must balance its proven efficacy against its specific safety considerations—notably QTc prolongation and orthostatic hypotension—ensuring that treatment is tailored to the individual patient’s cardiovascular and metabolic health.

Check Availability in India:

References

1. Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia — A New Chemical Entity Opening New Horizons in Psychiatric Innovation. PR Newswire. February 20, 2026. URL: https://vandapharmaceuticalsinc.gcs-web.com/node/16771/pdf
2. BYSANTI™ (milsaperidone) tablets, for oral use [Full Prescribing Information]. Vanda Pharmaceuticals Inc. Revised February 2026. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220358Orig1s000lbl.pdf
3. Potkin SG, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4-S11. URL: https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-fda-approval-bysantitm-milsaperidone-treatment
4. Cutler AJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20-S28. URL: https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-fda-approval-bysantitm-milsaperidone-treatment
5. Weiden PJ, et al. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study. J Clin Psychopharmacol. 2016;36(4):302-308. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4982888/
6. Torres R, et al. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024;85(1):23m14966. URL: https://pubmed.ncbi.nlm.nih.gov/38236020/
7. Vanda Pharmaceuticals. ASCP 2025 poster on milsaperidone–iloperidone bioequivalence (PDF). May 2025. URL: https://www.vandapharma.com/pdfs/milsaperidone-BE-poster-ASCP-2025-v9-final-23may2025.pdf
8. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile. Clin Schizophr Relat Psychoses. 2011;5(2):98-108. URL: https://med.uth.edu/psychiatry/2026/02/23/fda-approval-of-bysanti-milsaperidone-a-new-option-for-bipolar-i-disorder-and-schizophrenia/
9. Stewart J. Bysanti (milsaperidone) FDA Approval History. Drugs.com. February 23, 2026. URL: https://www.drugs.com/history/bysanti.html
10. Holmberg M. FDA Approval of Milsaperidone Widens Door to Severe Mental Disorder Treatment. MedCentral. February 21, 2026. URL: https://www.medcentral.com/psychiatry/fda-decision-milsaperidone-bysanti-for-bipolar-1-schizophrenia
11. Kalkman HO, et al. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):553-60. URL: https://www.researchgate.net/publication/11370746_Receptor_profile_of_P88-8991_and_P95-12113_metabolites_of_the_novel_antipsychotic_iloperidone
12. Dunleavy K. Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months. Fierce Pharma. February 23, 2026. URL: https://www.fiercepharma.com/pharma/vanda-gains-2nd-new-drug-approval-many-months-nod-bysanti
13. Xtalks. Bysanti FDA Approval for Bipolar I and Schizophrenia Marks Vanda’s Second Win in Two Months. February 2026. URL: https://xtalks.com/bysanti-fda-approval-for-bipolar-i-and-schizophrenia-marks-vandas-second-win-in-two-months-4664/
14. Walters J. FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia. Psychiatric Times. February 20, 2026. URL: https://www.psychiatrictimes.com/view/fda-approves-bysanti-for-treatment-of-bipolar-1-disorder-and-schizophrenia